Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

277 results about "Influenza A neuraminidase" patented technology

Neuraminidase enzymes are a large family, found in a range of organisms. The best-known neuraminidase is the viral neuraminidase, a drug target for the prevention of the spread of influenza infection. The viral neuraminidases are frequently used as antigenic determinants found on the surface of the influenza virus.

DNA transfection system for the generation of infectious influenza virus

The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC

Influenza vaccines

InactiveUS20080299151A1Less protectionBroad and efficient protective immunitySsRNA viruses negative-senseOrganic active ingredientsHemagglutininMammal
Described herein are vaccines and the use of naked DNA and / or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and / or the 1957 H2N2 and / or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and / or RNA encoding Neuraminidase (NA) and / or matrix protein (M) and / or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and / or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed.
Owner:STATENS SERUM INST

Gynaecologic multi-item dry chemical united detection test paper strip and its measuring method

The invention relates to a test paper tape which can be used in the gynecological multiprogramming dry-chemistry joint detection. The test paper tape provided by the utility model comprises a dry-chemistry multiprogramming detection test paper tape which consists of a plastic substrate tape and various solidified regent blocks, and sample diluent. The dry regent blocks include combinations formed by increasing or decreasing at least three or more regent blocks of a Ph test regent block, a lactic acid regent block, a hydrogen peroxide concentration regent block, a leukocyte esterase concentration regent block, a neuraminidase activity regent block, an amine test regent block, a proline aminopeptidase substrate reagent block, an oxidase substrate reagent block, a N-acetylamine hexosidase substrate reagent block, a trichomonas specific protease substrate hydrolysis reagent block. the gynecological multiprogramming dry-chemistry joint detection test paper test provided by the utility model can detect Ph, lactic acid, hydrogen peroxide, leukocyte esterase, neuraminidase, amine test, proline aminopeptidase, oxidase, N-acetylamine hexosidase and trichomonas specific protease which are contained in leucorrhea sample at the same time, and can accurately reflect the microorganism environment of a women reproductive tract, the cleanness of leucorrhea secretion and the conditions of Candida albicans, trichomonas, gonococcus and the pathogens of bacterial vaginosis, thereby making the gynecological trichomonas detection more comprehensive; besides, the test paper tape provided by the utility model can be used easily and conveniently, and results can be obtained quickly. If the test paper tape is used together with a gynecological dry-chemistry analyzer, the operation can become easier and the result can be obtained more quickly.
Owner:杭州健宝医疗器械有限公司

Fucosan sulphate, preparation method thereof, and application of fucosan sulphate in preparing anti-influenza virus medicine

The invention belongs to the field of marine medicines, and relates to a fucosan sulphate, a preparation method thereof and application of the fucosan sulphate in preparing an anti-influenza virus medicine. Polysaccharide with a main chain taking alpha-1,2-D-mannose and beta-1,4-D-glucuronic acid as repetitive units, and with a branched chain of alpha-1,3-L-fucosan sulphate is obtained by virtue of hot-water extraction, calcium chloride precipitation and DEAE-Cellulose chromatographic column purification. The fucosan sulphate prepared by the invention is high in inhibition effect on the influenza virus neuraminidase activities of A H1N1, H5N1 and H3N2, and obvious in protection effect on the dog kidney epithelial cells infected by A H1N1. The fucosan sulphate provided by the invention has the advantages of being rich in raw material source, simple in preparation process, easy to industrialize, high in product water solubility, high in stability, free from toxic and side effects, and the like, and has the prospect of being developed to the anti-influenza virus medicine.
Owner:威海人生药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products